CARBOGEN AMCIS' SHANGHAI SITE
CARBOGEN AMCIS announces successful ANVISA audit of its facility in China
19 mars 2024 13h58 HE | CARBOGEN AMCIS INNOVATIONS AG
CARBOGEN AMCIS announces successful completion of its first Brazilian Regulatory Authority Agency (ANVISA) routine inspection of its Shanghai facility
Logo DIPHARMA.jpg
Dipharma Receives the 2nd GMP Certification from Brazilian ANVISA
26 oct. 2023 03h59 HE | Dipharma Francis S.r.l
MILAN, Italy, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Dipharma Francis S.r.l. (Dipharma), a leading Contract Development and Manufacturing Organization (CDMO) and a global manufacturer of Active...
Logo 400x400.jpg
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
31 août 2023 07h00 HE | CytoSorbents
PRINCETON, N.J., Aug. 31, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat...
Logo DIPHARMA.jpg
Dipharma receives GMP certification from Brazilian ANVISA
01 déc. 2022 08h46 HE | Dipharma Francis S.R.L
MILAN, Italy, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Dipharma Francis S.r.l. (Dipharma), a leading Contract Development and Manufacturing Organization (CDMO) and a global manufacturer of Active...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Receives Brazilian Health Regulatory Agency (ANVISA) Approval for COVISTIX™ (COVID-19 Virus Antigen Detection Test) for Brazil
03 nov. 2021 10h06 HE | Sorrento Therapeutics, Inc.
COVISTIX now approved for point of care use in symptomatic patients by ANVISA (national agency for approval of food, cosmetics, and medical devices) in Brazil.Commercialization in progress with...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line Clinical Data Expected End of 3Q21
22 juin 2021 09h00 HE | Sorrento Therapeutics, Inc.
Phase 2 US clinical trial of Abivertinib randomized last patient (#96) on 4/07/2021.Phase 2 Brazilian clinical trial of Abivertinib randomized last patient (#400) on 06/20/2021.Studies are...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Pivotal Clinical Trial of COVI-MSC™ in Hospitalized COVID-19 Patients With Acute Respiratory Distress Syndrome
20 mai 2021 09h00 HE | Sorrento Therapeutics, Inc.
Brazil Phase 2 Pivotal clinical trial of COVI-MSC is now authorized to proceed.The study will compare therapy using mesenchymal stem cells to placebo (and standard of care) in 100 COVID-19 patients...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Therapeutics’ Large Phase 2 Clinical Trial of Abivertinib in Mild, Moderate and Severe COVID-19 Patients
14 oct. 2020 11h57 HE | Sorrento Therapeutics, Inc.
Phase 2 clinical trials of Abivertinib now cleared to proceed in both Brazil and the U.S.Studies are complementary and address both dose duration and disease stageRapid enrollment expected for both...
logo.jpg
Earth Science Tech, Inc. Shares Progress on its Cannabis (CBD) Patent Formulas
10 juil. 2018 08h35 HE | Earth Science Tech, Inc.
DORAL, Florida, July 10, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and...